News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
Pfizer and BioNTech have released results from a Phase 2/3 trial showing a favorable safety profile and robust neutralizing antibody responses in children aged 5 to 11 years old.
Synthetic DNA vector producer, Touchlight, has announced the extension of its fundraising round to a current aggregate total of US$125m (£92m). The financing was led by Bridford Investments Limited and Novator Partners.
Dutch group, Intravacc, has launched a hybrid business model that it believes will fuel growth and innovation.
Gritstone bio, Inc., has dosed the first volunteer in a Phase 1 trial for a self-amplifying mRNA second-generation COVID-19 vaccine booster.
Paid for and content provided by Thermo Fisher Scientific
Meeting microbiological standards is extremely hard without an environment that speaks to cleanliness: ultimately facilities don’t get compliant, they stay compliant.